Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Novavax's enterprise value is CHF841.7 Mil.
Novavax's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was CHF-163.8 Mil. Therefore, Novavax's EV-to-EBITDA for today is -5.14.
The historical rank and industry rank for Novavax's EV-to-EBITDA or its related term are showing as below:
XSWX:NVAX'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -126.71 Med: -2.88 Max: 2.92
Current: -5.12
During the past 13 years, the highest EV-to-EBITDA of Novavax was 2.92. The lowest was -126.71. And the median was -2.88.
XSWX:NVAX's EV-to-EBITDA is ranked worse than 100% of 406
companies
in the Biotechnology industry
Industry Median: 14.4
vs XSWX:NVAX: -5.12
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2026-08-22), Novavax's stock price is CHF7.242.
Novavax's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was CHF-1.210. Therefore, Novavax's PE Ratio (TTM) for today is At Loss.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Novavax's share price for today is CHF7.242.
Novavax's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF-1.210.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Novavax's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:NVAX vs JBIO, AVLN, TRAX: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Novavax's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Novavax EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Novavax's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Novavax's EV-to-EBITDA falls into.
Novavax's current Enterprise Value is CHF841.7 Mil.
Novavax's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF-163.8 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Novavax (XSWX:NVAX) has a EV-to-EBITDA of -5.14 as of Aug. 22, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Novavax. According to the industry distribution chart, Novavax ranks #999999 out of 406 companies in the Biotechnology industry.
Is Novavax's EV-to-EBITDA too high?
Novavax's current EV-to-EBITDA is -5.14. Based on the distribution chart, Novavax ranks #999999 out of 406 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Novavax has a GF Score™ of 46/100, reflecting its overall financial health beyond just this single metric.
How does Novavax's EV-to-EBITDA compare to JBIO and AVLN?
According to the Biotechnology industry distribution chart, Novavax ranks #999999 out of 406 companies for EV-to-EBITDA. This places Novavax in the lower half of its industry. The industry median EV-to-EBITDA is 14.40. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 14.40, based on 406 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Novavax. For the Biotechnology industry, the median EV-to-EBITDA is 14.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Novavax's current EV-to-EBITDA is -5.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novavax stock overvalued right now?
Novavax (XSWX:NVAX) has a current EV-to-EBITDA of -5.14. The stock's GF Value™ is CHF2.58, compared to a current price of CHF7.24 — trading 180.7% above its estimated fair value. The current EV-to-EBITDA is -5.14. Novavax's overall GF Score™ is 46/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Novavax (XSWX:NVAX), the current EV-to-EBITDA is -5.14 as of Aug. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Novavax (XSWX:NVAX) Overvalued in 2026?
Based on GuruFocus' analysis, Novavax stock appears to be overvalued.
The current stock price of CHF7.24 is trading 180.7% above its estimated GF Value™ of CHF2.58.
Key valuation signals for XSWX:NVAX:
EV-to-EBITDA: -5.14
GF Value™: CHF2.58 vs. price of CHF7.24 (180.7% above fair value)
No single metric tells the full story. See the XSWX:NVAX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.
46GF Score
Get the complete analysis for XSWX:NVAX
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:NVAX has been successfully added to your 
